Record Point is an independent corporate advisory firm specialising in domestic and international advisory services for public and private companies.
“We were highly impressed with the Record Point team’s lead role during the … sale. The team assisted us by providing the high quality deliverables and process management we have come to expect from advisors, but differentiated themselves through their considered insights and genuinely value-additive approach to M&A. First class execution in every respect.”
“Record Point were instrumental in the … sale process, adding value at every step through to the finish line. The ultimate transaction result that was delivered was far beyond our expectations and would not have been achieved without the dedication and diligence that the Record Point team demonstrated throughout the process.”
“What distinguishes [Record Point] is their clarity of communication, agility, candour, integrity, ability to align the interests of stakeholders and the tremendous informal support they provide to the team during a high value and large scale process.”
“Record Point added value to every step of the process providing my Board and me with commercial and pragmatic advice at all times.“
“Record Point was instrumental in assisting my management team and me on Project Mason. They are an exceptionally capable and professional team who were across the detail of all aspects of the deal.”
“We felt we were in safe and experienced hands throughout the sale processes and with Record Point managing the sale processes, we could continue to operate our business through to completion ensuring we hit our forecasts that potential acquirers were relying on.”
“In addition to enhancing the valuation of the offer, [Record Point] added a tremendous amount of value by assisting me and my team through the challenges of juggling running a business and executing a complex transaction…”
Record Point acts as lead advisor to GenesisCare on its acquisition of leading US radiation oncology and integrated cancer treatment provider, 21st Century Oncology.
The acquisition marks GenesisCare’s entry into the US market, establishing a truly global platform with a strong foothold in the world’s largest market for radiation oncology. This follows successful entries into the UK and Spain extending on the Australian business where the company was founded.
With a proven model globally, GenesisCare will be supporting the team at 21st Century Oncology and combining its innovative operating practices to ensure patients have increased access to high quality cancer treatments, expanding on its purpose to design care experiences that deliver the best possible life outcomes.
21st Century Oncology is the largest independent oncology provider in the US, headquartered in Florida. It operates 124 radiation oncology treatment centres in the US and 170 clinical sites across the country. Together, the combined network will operate almost 200 radiation oncology treatment centres.
Following the acquisition, GenesisCare plans to invest an additional US$300m in the US over the next three years. The investment is targeted towards an expansion of treatment options for patients, including installation of state-of-the-art equipment and an expanded clinical footprint.
The transaction follows a major expansion capital raise undertaken in 2018, where Record Point advised GenesisCare on almost A$1bn in debt funding and an equity investment from KKR.
The sale of 21st Century Oncology is subject to customary regulatory reviews, and is expected to close through the early months of 2020.